Cingulate Inc. CING

CING Company Overview

Cingulate Inc. (NASDAQ: CING) is a clinical-stage biopharmaceutical company focused on developing and commercializing precision-timed pharmaceutical products, primarily for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety-related disorders. The company operates within the biotechnology and specialty pharmaceutical industries, with a strategic emphasis on reformulating approved active pharmaceutical ingredients using proprietary drug delivery technologies designed to optimize therapeutic duration and symptom control. Its core revenue strategy is currently tied to advancing product candidates through clinical development and eventual regulatory approval rather than commercial product sales, as the company remains in the pre-commercial stage according to public filings.

The company’s primary product portfolio includes ADHD candidates such as CTx-1301 and anxiety-focused candidates including CTx-2103, both utilizing the company’s proprietary Precision Timed Release (PTR) platform technology. Cingulate positions itself around differentiated dosing profiles intended to provide extended symptom coverage while potentially reducing dosing frequency and treatment variability. The company was founded in 2012 and is headquartered in Kansas City, Kansas. Since its inception, it has evolved from an early-stage formulation research company into a publicly traded clinical-stage pharmaceutical developer, including its listing on Nasdaq following an initial public offering.